TB drug liver risk under the microscope
NCT ID NCT07472348
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will track 220 adults being treated for tuberculosis (TB) or latent TB with the drug isoniazid. Researchers want to see how often the drug causes liver injury and what factors make it more likely. They will also look at how doctors manage this side effect in real-world practice. The goal is to make TB treatment safer by better understanding and preventing liver damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isoniazid
- What this could lead to
- If successful, this study could help doctors identify who is at risk of liver injury from isoniazid and manage it better, making TB treatment safer.
- What could go wrong
- This is an observational study, not a trial testing a new treatment. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Fatebenefratelli Sacco Hospital
Milan, Italy, 20157, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A mobile x-ray van with AI could spot TB before it spreads
- AI-Powered skin patch could bring TB prevention to People's doorsteps
- Can new tests predict who will develop active TB?
- Community-Driven TB screening aims to reach vulnerable immigrants
- Shorter TB regimens could simplify treatment
- Could aspirin or ibuprofen help beat TB faster?